1. Home
  2. IPHA vs SGMT Comparison

IPHA vs SGMT Comparison

Compare IPHA & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.82

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$11.09

Market Cap

676.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
IPHA
SGMT
Founded
1999
2006
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.3M
676.3M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
IPHA
SGMT
Price
$1.82
$11.09
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
8
Target Price
$5.75
$26.13
AVG Volume (30 Days)
35.5K
865.8K
Earning Date
03-26-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,000,000.00
Revenue This Year
$180.36
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.18
$4.50
52 Week High
$2.71
$11.45

Technical Indicators

Market Signals
Indicator
IPHA
SGMT
Relative Strength Index (RSI) 39.55 61.34
Support Level $1.67 $6.60
Resistance Level $1.88 $11.30
Average True Range (ATR) 0.11 0.55
MACD -0.03 -0.07
Stochastic Oscillator 4.55 77.98

Price Performance

Historical Comparison
IPHA
SGMT

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: